Showing results (141-150 of 161) with videos related to
Sort By:
Pageof 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 17, 2022
Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)Samuel R Schnittman, Michael T Lu, Thomas Mayrhofer, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 5, 2024
Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIVMaheen Z Abidi, Triin Umbleja, Edgar T Overton, et al.The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.JAMA Network Open|June 29, 2021
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular PreventionUdo Hoffmann, Michael T Lu, Borek Foldyna, et al.The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionChloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2022
Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United StatesMarkella V Zanni, Borek Foldyna, Sara McCallum, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapySara E Looby, Amy Kantor, Tricia H Burdo, et al.HIV Research & Clinical Practice|March 13, 2020
Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordinationKathleen V Fitch, Emma M Kileel, Sara E Looby, et al.Pageof 17